Live-born children after assisted reproduction in women with type 1 diabetes and type 2 diabetes: a nationwide cohort study

Michael Due Larsen1,2 • Dorte Møller Jensen3,4 • Jens Fedder5,6 • Line Riis Jølving2,7 • Bente Mertz Nørgård2,7

Received: 7 February 2020 / Accepted: 23 April 2020
© The Author(s) 2020

Abstract
Aims/hypothesis Type 1 and type 2 diabetes are among the most prevalent chronic diseases in women in the fertile years and women with diabetes may experience several reproductive issues. We aimed to examine the chance of biochemical pregnancy, clinical pregnancy and live birth after assisted reproductive technology (ART) treatment in women with type 1 and type 2 diabetes and whether obesity per se influenced the results.

Methods This nationwide register-based cohort study is based on the Danish ART Registry comprising 594 women with either type 1 diabetes or type 2 diabetes from 2006 to 2017.

Results Relative to women without diabetes, the adjusted OR (95% CI) of a live birth per embryo transfer was 0.50 (0.36, 0.71) in women with type 2 diabetes and 1.10 (0.86, 1.41) in women with type 1 diabetes.

Conclusions/interpretation Our data on the efficacy of ART treatment in women with type 1 and type 2 diabetes is the first in this field. When compared with women without diabetes, women with type 1 diabetes had an equivalent chance of a live birth per embryo transfer whereas women with type 2 diabetes had a reduced chance. The findings in women with type 2 diabetes did not seem to be driven by obesity per se as the same pattern was seen in both normal-weight and obese women.

Keywords Assisted reproductive technology • Body mass index • Cohort study • Denmark • Embryo transfer • Epidemiology • In vitro fertilisation • Infertility • Type 1 diabetes • Type 2 diabetes

Introduction
Type 1 and type 2 diabetes are among the most prevalent chronic diseases in women in their fertile years [1]. The state of autoimmunity is well known in type 1 diabetes [2, 3], and women with type 1 diabetes may experience several reproductive problems. Observational studies have shown an increased risk of anencephaly, microcephaly, congenital heart disease, and caudal regression, and optimising glycaemic control prior to conception is found to be associated with the lowest risk of
congenital anomalies and stillbirth [4]. In addition, women with type 1 diabetes have fewer offspring than other women even though the levels of involuntary infertility has been observed to be similar to healthy women [5, 6]. In type 1 diabetes, hyperglycaemia due to insulin deficiency and hyperinsulinaemia due to exogenous insulin administration can induce hypogonadism, polycystic ovarian morphology and hyperandrogenism, resulting in decreased fertility [7]. Type 2 diabetes is associated with metabolic traits like polycystic ovary syndrome, obesity, insulin resistance and chronic inflammation. In general, both type 1 and type 2 diabetes are associated with a number of reproductive problems including reduced fertility, early and late pregnancy loss, congenital malformations, vascular stress, hypertensive disorders in pregnancy, preterm labour and infections [8–14]. These conditions are more prevalent in obese women compared with normal-weight women even in the absence of diabetes [15, 16].

Assisted reproductive technology (ART) treatment is a relevant intervention in women who cannot conceive naturally. However, recently published studies have suggested that women with rheumatoid arthritis, Crohn’s disease, ulcerative colitis and hyperthyroidism have a decreased chance of producing a live-born child after ART treatment compared with women without these conditions [17–20]. The studies also indicate that the decreased chance of a live birth might be due to failure to achieve a biochemical pregnancy and not a failure to carry the pregnancy to term. These diseases have an autoimmune aetiology, although the underlying mechanisms and the role of autoimmunity and/or chronic inflammation has yet to be examined. We aimed to examine the efficacy of ART treatment in a large group of women with type 1 and type 2 diabetes, representing women with underlying autoimmunity and chronic inflammation, respectively. Based on nationwide Danish data we thus examined the chance of biochemical pregnancy, clinical pregnancy and live birth after embryo transfer. Further, we aimed to study whether obesity per se influenced the results.

Methods

Based on Danish health registries, this nationwide cohort study comprised all embryo transfers in Denmark from 2006 to December 2017, including follow-up on childbirths until the end of 2018. All citizens in Denmark (approximately 5.7 million inhabitants, >90% of European descent) have a unique civil registration number [21]. This number is assigned to all residents at birth and is used across all Danish health registries for valid record linkage on an individual level. We obtained the following data: (1) data related to ART procedures and cause of infertility and pregnancy from the Danish ART Registry [22, 23]; (2) data on exposure and comorbid diseases from The Danish National Patient Registry (DNPR) [24]; (3) data on the outcome of infertility treatment (live birth) from the Danish Medical Birth Registry (DMBR) [25]; and (4) data on death and immigration from The Civil Registration System [21].

Setting and study population Denmark has a uniform organised healthcare system and there is equal and free access to the tax-supported healthcare services, including ART treatment. Couples with fertility problems, and single women, are
offered up to three in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) treatment cycles with fresh embryos, and an unlimited number of frozen embryo transfers, if the woman’s age does not exceed 41 years (46 years in the private sector).

The study population comprised all women registered in the ART registry with at least one embryo transfer during the study period. The Danish ART Registry contains all treatment cycles performed in both public and private clinics [22, 23]. In this study, the term ART treatment refers to IVF (with or without fertilisation with ICSI) and transfer of frozen–thawed (frozen embryo replacement [FER]) embryos.

Exposed and unexposed cohort

The exposed cohorts of embryo transfers in women with type 1 and type 2 diabetes were identified using the DNPR. The DNPR records all discharges from Danish hospitals since 1977 and all outpatient visits since 1994 [24]. Information in the DNPR includes details of the hospital, department, dates of admission and discharge, procedures performed and discharge diagnoses based on the International Classification of Diseases: ICD-8 before 1994 (http://www.wolfbane.com/icd/icd8.htm); ICD-10 from 1994 onwards (http://apps.who.int/classifications/icd10/browse/2016/en); ICD-9 was never used in Denmark. Diabetes coding in the DNPR has changed over time, with a single ICD-8 code of 250 in the period 1977–1986, and from 1987–1993 it changed to ICD-8 code 249 for type 1 diabetes and ICD-8 code 250 for type 2 diabetes. From 1994 onwards we used ICD-10 E10 codes for type 1 diabetes and ICD-10 E11 codes for type 2 diabetes.

Preliminary analyses revealed that 37% of the women had registered diagnostic codes for both type 1 and type 2 diabetes in the DNPR records. To avoid misclassification of types of diabetes in our analyses we defined three exposed groups: type 1 diabetes, type 2 diabetes and uncategorised diabetes. First, we included all women who had at least two discharge diagnoses of type 1 diabetes or type 2 diabetes at any time before the date of embryo transfer. Women belonging to the type 1 diabetes cohort had never had codes for type 2 diabetes, and those belonging to the type 2 diabetes cohort had never had codes for type 1 diabetes. Women who had only one diagnosis of type 1 or type 2 diabetes before embryo transfer or who had a mixture of diabetes diagnostic codes were considered to have uncategorised diabetes. We could not distinguish the type of diabetes before 1987 and therefore we started the construction of the diabetes cohorts based on data from January 1987.

The unexposed cohort comprised all embryo transfers in women without diagnoses of diabetes before the date of embryo transfer.

Outcomes

We examined live births within a period of 140–308 days after the date of embryo transfer. We identified the information regarding live birth after ART treatment from the DMBR. The DMBR includes information on all births in Denmark since 1 January 1973 and includes information on the mother, the child and birth-related diagnoses [25, 26]. Live birth was thus considered to be the result of the particular ART treatment if the difference between embryo transfer and birth was 20–44 weeks (corresponding to 140–308 days) [17] from the start of the last menstruation. We also estimated the chance of biochemical pregnancy and clinical pregnancy as outcomes, with the purpose of estimating the women’s ability to conceive after embryo transfer. Biochemical pregnancy outcome was based on information from the ART registry (positive test for human chorionic gonadotropin measured at 14–16 days after embryo transfer) and clinical pregnancy was based on the result of an ultrasound examination approximately 7–8 weeks after embryo transfer.

Statistical analyses

Contingency tables were constructed for the main study variables according to the three exposed cohorts and the unexposed cohort. Because each woman could have several ART treatments during the study period, the observation unit was the embryo transfer. We used multilevel logistic regression analyses to compute the crude and the adjusted RR estimates as ORs with 95% CIs for the outcomes following ART treatments in women with type 1, type 2 and uncategorised diabetes relative to women without any codes of diabetes registered. The model accounted for multiple embryo transfers in the same woman. The analyses on the chance of having a positive clinical pregnancy were based on only those women who had a positive biochemical pregnancy.

Data on possible confounders

Data on possible confounders were obtained from the ART registry, beside data on parity and comorbid disease which were obtained from the DNPR. For classifying comorbid disease we used the Charlson comorbidity index at the time of each embryo transfer [27]. The covariates included in the regression models were selected using the modified disjunctive cause criterion [28] and the following adjustments were used in the final model: the woman’s age; cause of infertility (female factor, male factor, combined female/male factor, idiopathic infertility); calendar year of ART treatment; BMI in four categories corresponding to the WHO classification; and the partner’s smoking and alcohol intake at the time of embryo transfer. Adjusting for comorbidity in the regression model had no impact on the final estimates and was not included in final model. In subanalyses, we stratified type 2 diabetes according to BMI (normal weight or overweight/obese).

Results

We identified 187 women with type 1 diabetes and 170 women with type 2 diabetes, undergoing 538 and 518 embryo
transfers, respectively, during the study period of 2006–2017 (Table 1). We found 237 (40%) women whose diabetes we could not categorise as either type 1 or type 2 diabetes, using the DNPR. The unexposed cohort comprised a total of 127,599 embryo transfers in 42,688 women without a history of diabetes before embryo transfer. The median age of the women and their partners was similar in the exposed and unexposed cohorts. Women with type 2 diabetes were more likely to undergo IVF (45.4%) than ICSI (29.8%). The proportions of women with type 1 diabetes receiving IVF and ICSI

Table 1 Descriptive characteristics of the study cohorts of ART treatments in women with a history of type 1 diabetes, type 2 diabetes or uncategorised diabetes and without a history of diabetes during the study period (1 January 2006 to 31 December 2017)

| Characteristic                              | Exposed cohort                                                                 | Unexposed cohort                                                                 |
|---------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Embryo transfers in women with type 1 diabetes \((N=538)^a\) | Embryo transfers in women with type 2 diabetes \((N=518)^b\) | Embryo transfers in women with uncategorised diabetes \((N=682)^c\) |
| Median (25th–75th percentile) age at embryo transfer, years | 34 (30–38) | 36 (32–38) | 35 (32–38) | 34 (30–38) |
| Median (25th–75th percentile) partner’s age at embryo transfer, years | 36 (32–39) | 37 (33–40) | 36 (33–41) | 36 (32–40) |
| Female/male factor infertility, n (%)       | Female factor 97 (18.0) | 93 (18.0) | 130 (19.1) | 19,275 (15.1) |
|                                           | Male factor 168 (31.2) | 112 (21.6) | 191 (28.0) | 40,990 (32.1) |
|                                           | A mixture of factors/idiopathic 273 (50.7) | 313 (60.4) | 361 (52.9) | 67,270 (52.7) |
| Type of preceding treatment, n (%)          | IVF 192 (36.6) | 229 (45.4) | 271 (40.1) | 47,061 (37.2) |
|                                           | ICSI 206 (39.2) | 150 (29.8) | 247 (36.6) | 47,935 (37.9) |
|                                           | FER 127 (24.2) | 125 (24.8) | 157 (23.3) | 31,490 (24.9) |
| BMI, n (%)                                  | <18.5 kg/m² (underweight) 15 (3.4) | 0 (0.0) | 3 (0.5) | 3518 (3.4) |
|                                           | 18.5–25 kg/m² (normal weight) 234 (53.3) | 71 (17.7) | 188 (33.8) | 67,002 (64.1) |
|                                           | 25–30 kg/m² (pre-obesity) 130 (29.6) | 138 (34.4) | 162 (29.1) | 23,990 (23.0) |
|                                           | 30–35 kg/m² (obese I) 54 (12.3) | 142 (35.4) | 155 (27.9) | 8189 (7.8) |
|                                           | ≥35 kg/m² (obese II–III) 6 (1.4) | 50 (12.5) | 48 (8.6) | 1796 (1.7) |
| Smoking at the time of embryo transfer, n (%) | 38 (8.6) | 48 (12.1) | 60 (10.8) | 8684 (8.4) |
| Alcohol consumer, n (%)                     | 191 (45.4) | 78 (21.3) | 158 (30.0) | 44,636 (44.8) |
| Calendar year of infertility treatment, n (%) | 2006–2009 189 (35.1) | 199 (38.4) | 258 (37.8) | 38,259 (30.0) |
|                                           | 2010–2013 161 (29.9) | 165 (31.9) | 253 (37.1) | 42,305 (33.2) |
|                                           | 2014–2017 188 (34.9) | 154 (29.7) | 171 (25.1) | 47,035 (36.9) |
| Parity, n (%)                               | 0 197 (36.6) | 162 (31.3) | 269 (39.4) | 49,612 (38.9) |
|                                           | 1+ 341 (63.4) | 356 (68.7) | 413 (60.6) | 77,987 (61.1) |
| Comorbidity at embryo transfer, n (%)       | No comorbidity 431 (80.1) | 419 (80.9) | 559 (82.0) | 113,726 (89.1) |
|                                           | Some comorbidity 107 (19.9) | 99 (19.1) | 123 (18.0) | 13,873 (10.9) |

\(^a\) No. of women in the exposed type 1 diabetes cohort: 187. Percentage with missing data: age of partner 8.8%, ART treatment 2.4%, BMI 18.4%, smoking at the time of embryo transfer 18.0%, alcohol 21.7%.

\(^b\) No. of women in the exposed type 2 diabetes cohort: 170. Percentage with missing data: age of partner 7.5%, ART treatment 2.7%, BMI 22.6%, smoking at the time of embryo transfer 23.4%, alcohol 29.2%.

\(^c\) No. of women in the exposed uncategorised diabetes cohort: 237. Percentage with missing data: age of partner 5.4%, ART treatment 1.0%, BMI 18.5%, smoking at the time of embryo transfer 18.2%, alcohol 22.9%.

\(^d\) No. of women without a history of diabetes cohort: 42,688. Percentage with missing data: age of partner 6.8%, fertility factor 0.1%, ART treatment 2.4%, BMI 18.1%, smoking at the time of embryo transfer 18.9%, alcohol 22.0%.
was similar (36.6% and 39.2%, respectively) and comparable with those seen in women unexposed to diabetes.

In general, women in the diabetes cohorts had a higher BMI than women in the unexposed cohort. We found that 82.3% of the women with type 2 diabetes had a BMI classified as pre-obese or obese (Table 1). In women with type 1 diabetes, 53.3% were normal weight and 64.1% of the unexposed women were classified normal weight. Smoking and alcohol consumption differed among the groups of women. Those with type 2 diabetes were more likely to smoke at the time of embryo transfers compared with the unexposed group (12.1% and 8.4%, respectively). On the contrary, 78.7% of women with type 2 diabetes were registered as having no alcohol use whereas among both women with type 1 diabetes and those unexposed to diabetes, approximately 55% did not consume alcohol.

**Live birth and biochemical and clinical pregnancy**

The chance of biochemical pregnancy, and of clinical pregnancy, after each embryo transfer in women with type 1 diabetes, type 2 diabetes and uncategorised diabetes are shown in Table 2. In women with type 1 diabetes undergoing ART treatment, the chance of a biochemical pregnancy and clinical pregnancy was not decreased (adjusted OR [95% CI] 1.00 [0.79, 1.26] and 1.36 [0.81, 2.29], respectively). In women with type 2 diabetes the adjusted OR of a biochemical pregnancy after an embryo transfer was 0.57 (95% CI 0.43, 0.76) and the adjusted OR of a clinical pregnancy detected by an ultrasound examination was 0.91 (95% CI 0.50, 1.66).

A total of 26.4% of the women with type 1 diabetes had a live-born child after embryo transfer, and this proportion was similar to that seen in the women in the unexposed cohort (23.9%), corresponding to a crude OR of 1.14 (95% CI 0.91, 1.43) for live birth and an adjusted OR of 1.10 (95% CI 0.86, 1.41) (Table 3). Only 13.5% of the women with type 2 diabetes had a live-born child after embryo transfer, and the chance of live birth was significantly reduced compared with the unexposed cohort (crude OR 0.46 [95% CI 0.34, 0.61] and adjusted OR 0.50 [95% CI 0.36, 0.71]). The adjusted OR for live birth in the group of women with uncategorised diabetes was 1.20 (95% CI 0.95, 1.51).

The subanalyses restricted to women with type 2 diabetes were stratified according to weight (normal and overweight/obese)

---

**Table 2** ORs for biochemical pregnancy and clinical pregnancy in women with type 1 diabetes, type 2 diabetes or uncategorised diabetes in the study cohorts of ART treatments during the study period (1 January 2006 to 31 December 2017)

| Pregnancy in women with type 1 diabetes, n (%) | Embryo transfers in exposed cohorts | Embryo transfers in unexposed cohort | Crude OR (95% CI) | Adjusted OR (95% CI) a |
|---------------------------------------------|-----------------------------------|------------------------------------|------------------|---------------------|
| Biochemical pregnancy (hCG)b               | Yes 202 (38.0)                    | 45,251 (35.9)                      | 1.10 (0.90, 1.35) | 1.00 (0.79, 1.26)   |
|                                            | No 330 (62.0)                     | 80,862 (64.1)                      |                  |                     |
| Clinical pregnancy (ultrasound)            | Yes 167 (83.5)                    | 36,725 (82.1)                      | 1.12 (0.74, 1.69) | 1.36 (0.81, 2.29)   |
|                                            | No 33 (16.5)                      | 8006 (17.9)                        |                  |                     |
| Pregnancy in women with type 2 diabetes, n (%) | Biochemical pregnancy (hCG)b     | Yes 131 (25.5)                     | 45,251 (35.9)    | 0.56 (0.44, 0.70)   |
|                                            | No 382 (74.5)                     | 80,862 (64.1)                      |                  | 0.57 (0.43, 0.76)   |
| Clinical pregnancy (ultrasound)            | Yes 101 (77.1)                    | 36,725 (82.1)                      | 0.72 (0.45, 1.15) | 0.91 (0.50, 1.66)   |
|                                            | No 30 (22.9)                      | 8006 (17.9)                        |                  |                     |
| Pregnancy in women with uncategorised diabetes, n (%) | Biochemical pregnancy (hCG)b     | Yes 217 (32.2)                     | 45,251 (35.9)    | 0.82 (0.68, 0.99)   |
|                                            | No 456 (67.8)                     | 80,862 (64.1)                      |                  | 0.98 (0.79, 1.21)   |
| Clinical pregnancy (ultrasound)            | Yes 181 (83.8)                    | 36,725 (82.1)                      | 1.13 (0.76, 1.70) | 1.40 (0.87, 2.24)   |
|                                            | No 35 (16.2)                      | 8006 (17.9)                        |                  |                     |

a Adjusted for women’s age, calendar year of treatment, cause of infertility (female factor, male factor, or a mixture of factors/idiopathic), BMI, smoking at the time of embryo transfer and alcohol consumed

b Missing hCG data: type 1 diabetes 6 (0.01%); type 2 diabetes 5 (0.01%); uncategorised diabetes 9 (0.01%)

hCG, human chorionic gonadotropin
obese). In women with normal weight and type 2 diabetes, we found a reduced chance for a live-born child following ART treatments (adjusted OR 0.37 [95% CI 0.16, 0.85]); overweight/obese women also had a reduced chance of a live-born child (adjusted OR 0.52 [95% CI 0.36, 0.77]) (Table 4).

Discussion

In this nationwide cohort study encompassing 11 years of data on assisted reproduction, we found that women with type 1 diabetes did not have a reduced chance of a biochemical pregnancy, clinical pregnancy or a live-born child after ART, compared with other women receiving ART. In contrast, the chance of a live birth after an embryo transfer in women with type 2 diabetes was significantly decreased, compared with embryo transfers in women without diabetes. Our results also indicate that the reason for the decreased chance of a live birth could be related to inadequate implantation, as the chances of a biochemical pregnancy was also reduced whereas clinical pregnancy was not reduced. Our analyses considered a number of confounders, including differences in maternal weight. Even when we stratified our analyses according to categories of weight in women with type 2 diabetes, we obtained robust results. We thus found a significantly reduced chance of live birth in women with type 2 diabetes in both those who were normal weight and those who were overweight/obese.

This is the first study to examine the chance of a live-born child in women with type 1 and type 2 diabetes receiving ART treatment and therefore our results cannot be directly compared with those of others. Our findings on the efficacy of ART treatment in women with type 1 diabetes are reassuring. A previous case series study from 1992 by Dicker et al, including five women receiving IVF treatment, found that women with type 1 diabetes have the same chance of success as other women if optimal metabolic control is attained [29]. A larger study on ART and pregnancy outcome according to BMI by Pinborg et al found a reduced pregnancy rate per embryo transfer for obese women, although these results did not include information on diabetes [30].

Findings in women with other autoimmune diseases have suggested a reduced chance of live birth after ART treatment (adjusted OR [95% CI] for a live birth after ART was 0.78 [0.67, 0.91] in women with ulcerative colitis, 0.61 [0.47, 0.79] in women with Crohn’s disease, 0.78 [0.65, 0.92] in women with rheumatoid arthritis and 0.80 [0.69, 0.93] in women with hyperthyroidism) [18–20]. The results of the present study are reassuring for women with type 1 diabetes with an autoimmune aetiology, since the women with type 1 diabetes had the same chance of a positive outcome for ART treatment as women without diabetes. The decreased efficacy of ART treatment in women with type 2 diabetes indicates that inflammation and not autoimmunity is important and may provide a focus for further investigation. Women with undiagnosed type 2 diabetes and high glucose levels at the time of conception have a higher risk of spontaneous abortion and offspring with congenital malformations [8]. In addition, type 2 diabetes is more often associated with obesity, chronic inflammation, vascular stress, hypertensive conditions in pregnancy, preterm labour, pregnancy loss and infections [9]. Several studies have reported that pregnancy outcomes in women with type 2 diabetes are similar or worse than outcomes in women with type 1 diabetes [10, 14, 31]. These complications linked to hyperglycaemia are aggravated by obesity and excessive gestational weight gain [11]. Another major problem is that women with type 2 diabetes receive multi-pharmacological treatment outside pregnancy, primarily with oral glucose-lowering agents, glucagon-like peptide-1 analogues,

Table 3  The chance of live birth in women with type 1 diabetes, type 2 diabetes or uncategorised diabetes in the study cohorts of ART treatments during the study period (1 January 2006 to 31 December 2017)

|                    | Embryo transfers in exposed cohort | Embryo transfers in unexposed cohort | Crude OR (95% CI) for live birth | Adjusted OR (95% CI) for live birtha |
|--------------------|-----------------------------------|-------------------------------------|---------------------------------|-------------------------------------|
| Women with type 1 diabetes, n (%) |                                   |                                     |                                 |                                     |
| Yes                | 142 (26.4)                        | 30,481 (23.9)                       | 1.14 (0.91, 1.43)               | 1.10 (0.86, 1.41)                   |
| No                 | 396 (73.6)                        | 97,118 (76.1)                       |                                 |                                     |
| Women with type 2 diabetes, n (%) |                                   |                                     |                                 |                                     |
| Yes                | 70 (13.5)                         | 30,481 (23.9)                       | 0.46 (0.34, 0.61)               | 0.50 (0.36, 0.71)                   |
| No                 | 448 (86.5)                        | 97,118 (76.1)                       |                                 |                                     |
| Women with uncategorised diabetes, n (%) |                               |                                     |                                 |                                     |
| Yes                | 157 (23.0)                        | 30,481 (23.9)                       | 0.92 (0.75, 1.13)               | 1.20 (0.95, 1.51)                   |
| No                 | 525 (76.0)                        | 97,118 (76.1)                       |                                 |                                     |

a Adjusted for women’s age, calendar year of treatment, cause of infertility (female factor, male factor, or a mixture of factors/idiopathic), BMI, smoking at the time of embryo transfer and alcohol consumed
antihypertensive drugs and cholesterol-lowering agents. Many of these drugs are potentially teratogenic and planning of pregnancy both regarding glycaemic control and review of medications is of major importance. Placenta studies have described changes in placental pathology, including villous immaturity, vascularisation, placent al infarction and trophoblastic basement membrane thickness, in women with vs without diabetes [32]. The histology differs according to the type of maternal diabetes and may be linked to maternal metabolic dysfunction such as chronic inflammation, insulin resistance, hyperglycaemia, obesity and hypertension. Still, the underlying mechanisms are not fully understood. The findings of the present study support the hypothesis that the phenotypical characteristics of type 2 diabetes (chronic inflammation and insulin resistance) may increase the risk of a poor pregnancy outcome at all stages of fertilisation until the birth of the child.

It is evident that being overweight has an adverse impact on fertility, pregnancy and the health of children born to women who are above the recommended BMI levels [33–35]. Our stratified analysis showed that women with type 2 diabetes who were classed as pre-obese and obese (BMI ≥25 kg/m²) had a reduced chance of a live-born child. These findings suggest that the reduced success of ART in women with type 2 diabetes is not driven only by obesity but by diabetes per se.

Overall, this study is based on an unselected nationwide population from Danish health registries, which have high completeness and validity [24, 25]. We were able to consider and control for the most important confounders: women’s age, year of ART treatment, type of ART treatment, cause of infertility and BMI. This design allowed complete follow-up of the study cohorts and our outcomes were retrieved independently of the exposure status, thereby preventing selection bias and differential misclassification of the outcome. The quality of the DNPR data concerning the diagnosis of type 1 diabetes has been found satisfactory for epidemiological studies, as the predictive value of a diagnosis registration was 96% and the corresponding completeness was 91% [36]. We only included women in the type 1 diabetes cohort if they had at least two registered diagnoses of type 1 diabetes (and they never had a type 2 diabetes diagnosis) and only included women into the type 2 diabetes cohort if they had at least two registered diagnoses of type 2 diabetes (and they never had a type 1 diabetes diagnosis) before embryo transfer to ensure a high accurate exposure assessment (preventing misclassification of the exposure). It is thus a strength that we can construct two diabetes cohorts where we believe that the diagnoses are unambiguous; if there was any doubt about the specific type of diabetes, women were assigned into the uncategorised diabetes group. The ART registry is based on complete and valid data, and it is mandatory to report all treatment cycles and measurements on biochemical and clinical pregnancies from both public and private clinics [22, 23]. Regarding our outcome measurements on live birth, the data from the DMBR have both very high completeness and validity as all new-born children are registered in the DMBR [25, 26]. Unfortunately, the DNPR and Danish ATR registers used in this study do not include information on HbA1c. Thus, we cannot rule out that women with type 2 diabetes might have worse glycaemic control than women with type 1 diabetes. However, Danish women undergoing fertility treatment are routinely tested for diabetes and those with high HbA1c are referred to a diabetologist or their general practitioner for treatment.

Our study also has limitations regarding unknown confounders, and residual confounding can never be ruled out in observational studies. In our main analyses, we have taken several confounders into consideration and we have no reason to believe that our main results are influenced by severe confounding. It would, however, have been useful to have

| Exposed cohort (embryo transfers in women with type 2 diabetes) | Unexposed cohort (embryo transfers in women without diabetes) | Crude OR (95% CI) | Adjusted OR (95% CI) a |
|---------------------------------------------------------------|---------------------------------------------------------------|-------------------|------------------------|
| Live birth in women with BMI 18.5–25 kg/m² (normal weight), n (%) |                                                                 |                   |                        |
| Yes 7 (9.9)                                                    | 16,766 (25.0)                                                 | 0.30 (0.13, 0.69) | 0.37 (0.16, 0.85)      |
| No 64 (90.1)                                                   | 50,236 (75.0)                                                 |                   |                        |
| Live birth in women with BMI ≥25 kg/m² (pre-obesity/obese III), n (%) |                                                               |                   |                        |
| Yes 45 (13.6)                                                  | 8042 (23.7)                                                  | 0.48 (0.33, 0.68) | 0.52 (0.36, 0.77)      |
| No 285 (86.4)                                                  | 25,933 (76.3)                                                |                   |                        |

Missing data on BMI are not included in analysis

a Adjusted for women’s age, calendar year of treatment, cause of infertility (female factor, male factor, or a mixture of factors/idiopathic), smoking at the time of embryo transfer and alcohol consumed
complete information on BMI and to be able to do stratified analyses according to disease severity and medical treatment of diabetes. However, the lack of such detailed clinical information did not allow us to do so. In our subanalyses on the impact of women’s weight, we examined subcohorts of women with type 2 diabetes. Here, the statistical precision was low due to the number of women in the exposed cohorts and BMI information was missing for 18% of the women. Further stratification into subgroups of BMI was not possible due to the low number of women with BMI ≥25 kg/m².

**Conclusion** Seeking help from ART has become commonplace and children born after ART treatment constitute 8% of the Danish national birth cohort [1, 37]. The increasing prevalence of type 2 diabetes in women during the reproductive period means that physicians can foresee treating and counselling an increasing number of women with type 2 diabetes. Hence, we need evidence on reproductive questions and the efficacy of ART treatment. Women starting the process of ART treatment expect information about their potential for a successful live birth and the advantages and disadvantages of ART treatment in general.

Our data on the efficacy of ART in women with type 1 and type 2 diabetes are the first data in this field. Women with type 1 diabetes had an equivalent chance of a live birth per embryo transfer when compared with women without diabetes whereas women with type 2 diabetes had a substantially reduced chance. The findings in women with type 2 diabetes did not seem to be driven by obesity per se as the same pattern was seen in both normal-weight and obese women. Prospective studies including characterisation of anthropometrics, glucose and lipid metabolism, treatment at the time of ART and biomarkers of chronic inflammation should be performed to confirm the findings in other settings and to address the mechanisms underlying these findings.

**Acknowledgements** The authors thank Merete Due Paarup, Imageconsult, Kolding, Denmark for graphic illustration. The authors thank M. D. Paarup, Imageconsult, Kolding, Denmark for the graphical abstract.

**Data availability** The study is notified at the Danish Data Protection Agency under the current joint notification of the Region of Southern Denmark (ref.no. 2012-58-0018, 17/37434). According to Danish law, ethical review board approval or patient consent are not required for non-interventional register-based studies. According to Danish legislation, our approval to use these registers for the current study do not allow us to distribute or make patient data directly available to other parties. The authors of this paper have no special access privileges to the data used in this study, and other researchers may apply for access to data through an application to the Research Service at the Danish Health Data Authority.

**Funding** Open Access funding provided by NTNU Norwegian University of Science and Technology (incl St. Olavs Hospital - Trondheim University Hospital). The study received support from Kong Christian den Tiendes Fond, Region of Southern Denmark.

**Authors’ relationships and activities** The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

**Contribution statement** MDL was involved in the study conception and design, data collection, data analyses, interpretation of results and manuscript writing and editing. LRJ was involved in data collection, data analyses, interpretation of results and manuscript editing. JF assisted with data analyses, interpretation of results and manuscript editing. DMJ obtained funding, interpreted results and edited the manuscript. BMN was involved in the study conception, funding and design, collected data and provided assistance with data analyses, interpretation of results and manuscript editing. All authors approved the final version of the manuscript. MDL and BMN are the guarantors of this work.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Jolving LR, Nielsen J, Kesmodel US, Nielsen RG, Beck-Nielsen SS, Norgard BM (2016) Prevalence of maternal chronic diseases during pregnancy - a nationwide population based study from 1989 to 2013. Acta Obstet Gynecol Scand 95(11):1295–1304. https://doi.org/10.1111/aogs.13007
2. Askenasy N (2016) Mechanisms of diabetic autoimmunity: I - the inductive interface between islets and the immune system at onset of inflammation. Immunol Res 64(2):360–368. https://doi.org/10.1007/s12026-015-8753-y
3. Askenasy N (2016) Mechanisms of diabetic autoimmunity: II – is diabetes a central or peripheral disorder of effector and regulatory cells? Immunol Res 64(1):36–43. https://doi.org/10.1007/s12026-015-8725-2
4. Jensen DM, Korsholm L, Ovesen P et al (2009) Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 32(6):1046–1048. https://doi.org/10.2337/dc08-2061
5. Jonasson JM, Brissmar K, Sparen P et al (2007) Fertility in women with type 1 diabetes: a population-based cohort study in Sweden. Diabetes Care 30(9):2271–2276. https://doi.org/10.2337/dc06-2574
6. Strommeyer ES, Steenkiste AR, Foley TP Jr, Berga SL, Doman JS (2003) Menstrual cycle differences between women with type 1 diabetes and women without diabetes. Diabetes Care 26(4):1016–1021. https://doi.org/10.2337/diacare.26.4.1016
7. Codner E, Merino PM, Tena-Sempere M (2012) Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum Reprod Update 18(5):568–585. https://doi.org/10.1093/humupd/dms024
8. Schafer-Graf UM, Dupak J, Vogel M et al (1998) Hyperinsulinism, neonatal obesity and placental immaturity in infants born to women...
with one abnormal glucose tolerance test value. J Perinat Med 26(1):27–36. https://doi.org/10.1515/jpm.1998.26.1.27
9. Kalagiri RR, Carder T, Choudhury S et al (2016) Inflammation in complicated pregnancy and its outcome. Am J Perinatol 33(14):1337–1356. https://doi.org/10.1055/s-0036-1582397
10. Clausen TD, Mathiesen E, Ekbom P, Hellmuth E, Mandrup-Poulsen T, Damm P (2005) Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 28(2):323–328. https://doi.org/10.2337/diabcare.28.2.323
11. Jensen DM, Ovesen P, Beck-Nielsen H et al (2005) Gestational weight gain and pregnancy outcomes in 481 obese glucose-tolerant women. Diabetes Care 28(9):2118–2122. https://doi.org/10.2337/diabcare.28.9.2118
12. Peppard HR, Marfori J, Iuorno MJ, Nestler JE (2001) Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 24(6):1050–1052. https://doi.org/10.2337/diabetes.24.6.1050
13. Thong EP, Codner E, Laven JSE, Teede H (2020) Diabetes: a metabolic and reproductive disorder in women. Lancet Diabetes Endocrinol 8(2):134–149. https://doi.org/10.1016/S2213-8587(19)30454-5
14. Dunne FP, Avalos G, Durkan M et al (2009) ATLANTIC DIP: pregnancy outcome for women with pregestational diabetes along the Irish Atlantic seaboard. Diabetes Care 32(7):1205–1206. https://doi.org/10.2337/dc09-1118
15. Hanson B, Johnstone E, Dorais J, Silver B, Peterson CM, Hotaling J (2016) Live birth and adverse birth outcomes in women with type 2 diabetes. Obstet Gynecol 128(2):389–394. https://doi.org/10.1097/AOG.0000000000002025
16. Pantasri T, Norman RJ (2014) The effects of being overweight and obese on female reproduction: a review. Gynecol Endocrinol 30(2):90–94. https://doi.org/10.3109/09513590.2013.850660
17. Friedman S, Larsen PV, Fedder J, Norgard BM (2017) The reduced chance of a live birth in women with IBD receiving assisted reproduction is due to a failure to achieve a clinical pregnancy. Gut 66(3):556–558. https://doi.org/10.1136/gutjnl-2016-311805
18. Norgard BM, Larsen MD, Friedman S, Knudsen T, Fedder J (2019) Decreased chance of a live born child in women with rheumatoid arthritis after assisted reproduction treatment: a nationwide cohort study. Ann Rheum Dis 78(3):328–334. https://doi.org/10.1136/annrheumdis-2018-214619
19. Norgard BM, Larsen PV, Fedder J, de Silva PS, Larsen MD, Friedman S (2016) Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn’s disease receiving assisted reproduction: a 20-year nationwide cohort study. Gut 65(5):767–776. https://doi.org/10.1136/gutjnl-2015-311246
20. Julving LR, Larsen MD, Fedder J, Friedman S, Norgard BM (2019) The chance of a live birth after assisted reproduction in women with thyroid disorders. Clin Epidemiol 11:683–694. https://doi.org/10.2147/CLEP.S208574
21. Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541–549. https://doi.org/10.1007/s10654-014-9930-3
22. Andersen AN, Westergaard HB, Olsen J (1999) The Danish in vitro fertilisation (IVF) register. Dan Med Bull 46(4):357–360
23. Westergaard HB, Johansen AM, Erb K, Andersen AN (2000) Danish National IVF Registry 1994 and 1995. Treatment, pregnancy outcome and complications during pregnancy. Acta Obstet Gynecol Scand 79(5):384–389
24. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490. https://doi.org/10.2147/CLEP.S91125
25. Bliddal M, Broe A, Pottegard A, Olsen J, Langhoff-Roos J (2018) The Danish Medical Birth Register. Eur J Epidemiol 33(1):27–36. https://doi.org/10.1007/s10654-018-0356-1
26. Kristensen J, Langhoff-Roos J, Skovgaard LT, Kristensen FB (1996) Validation of the Danish Birth Registration. J Clin Epidemiol 49(8):893–897. https://doi.org/10.1016/0895-4356(96)00018-2
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8
28. Lash TL, Fox MP, MacLehose RF, Maldonado G, McCandless LC, Greenland S (2014) Good practices for quantitative bias analysis. Int J Epidemiol 43(6):1969–1985. https://doi.org/10.1093/ije/dyu149
29. Dicker D, Ben-Rafael Z, Ashkenazi J, Feldberg D (1992) In vitro fertilization and embryo transfer in well-controlled, insulin-dependent diabetics. Fertil Steril 58(2):430–432. https://doi.org/10.1016/0015-0282(92)90007-8
30. Pinborg A, Gaarslev C, Hougaard CO et al (2011) Influence of female bodyweight on IVF outcome: a longitudinal multicentre cohort study of 487 infertility couples. Reprod BioMed Online 23(4):490–499. https://doi.org/10.1016/j.rbmo.2011.06.010
31. Confidential Enquiry into Maternal and Child Health (2005) Pregnancy in women with type 1 and type 2 diabetes in 2002–03. England, Wales and Northern Ireland. CEMACH, London. Available from https://elearning.rcog.org.uk/sites/default/files/Diabetes%20and%20other%20endocrinopathies/CEMACH_Pregnancy_type_1_2_diabetes.pdf
32. Huynh J, Dawson D, Roberts D, Bentley-Lewis R (2015) A systematic review of placental pathology in maternal diabetes mellitus. Placenta 36(2):101–114. https://doi.org/10.1016/j.placenta.2014.11.021
33. Broughton DE, Moley KH (2017) Obesity and female infertility: potential mediators of obesity’s impact. Fertil Steril 107(4):840–847. https://doi.org/10.1016/j.fertnstert.2017.01.017
34. Practice Committee of the American Society for Reproductive Medicine (2015) Obesity and reproduction: a committee opinion. Fertil Steril 104(5):1116–1126. https://doi.org/10.1016/j.fertnstert.2015.08.018
35. Supramaniam PR, Mittal M, McVeigh E, Lim LN (2018) The correlation between raised body mass index and assisted reproductive treatment outcomes: a systematic review and meta-analysis of the evidence. Reprod Health 15(1):34. https://doi.org/10.1186/s12978-018-0481-z
36. Nielsen GL, Sorensen HT, Pedersen AB, Sabroe S (1996) Analyses of data quality in registries concerning diabetes mellitus—a comparison between a population based hospital discharge and an insulin prescription registry. J Med Syst 20(1):1−10. https://doi.org/10.1007/bf02260869
37. Schmidt L (2006) Psychosocial burden of infertility and assisted reproduction. Lancet 367(9508):379–380. https://doi.org/10.1016/S0140-6736(06)68117-8

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.